| Name | Butyzamide |
| Description | Butyzamide is an effective and oral Mpl activator. It is a novel non-peptide-based molecule with antagonistic effects on thrombopoietin (TPO) receptors, which promotes proliferation of human Mpl (hMpl) expression and mouse pro B cell line Ba/F3. The phosphorylation of JAK2, STAT3, STAT5 and MAPK is induced. Butyzamide has been shown to help increase platelet levels in mouse xenotransplantation trials. |
| In vitro | Butyzamide (3 μM; 15 minutes) induces phosphorylation of JAK2, STAT3, STAT5, and MAPK in Ba/F3-hMpl cells.[1]
Butyzamide (3 μM; 48 hours) induces colony-forming unit-megakaryocyte (CFU-MK) and polyploid megakaryocyte formation in human CD34+ hematopoietic progenitor cells.[1] |
| In vivo | Butyzamide (10 mg/kg, 50 mg/kg; oral administration; once daily for 20 days) enhances human platelet levels in NOG mice transplanted with human fetal liver-derived CD34+ cells.[1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 165 mg/mL (278.93 mM), Sonication is recommended.
|
| Keywords | TPO | ThrombopoietinReceptor | Thrombopoietin Receptor | JAK | Butyzamide |
| Inhibitors Related | Undecane | Flubendazole | Esculin | Bisphenol A | HODHBt | Fumaric acid | Nifuroxazide | Balsalazide disodium dihydrate | Imidazole | Niclosamide | Afatinib | Lentinan |
| Related Compound Libraries | Reprogramming Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Stem Cell Differentiation Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | MAPK Inhibitor Library | Transcription Factor-Targeted Compound Library |